MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329403 | Name: Allisartan Isoproxil
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Allisartan isoproxil is an nonpeptide angiotensin II receptor blocker (ARB) precursor drug that is used to treat hypertension and reduce the risk of heart disease. Allisartan isoproxil alleviates diabetic cardiomyopathy by attenuating diabetes‑induced oxidative stress and inflammation through the SIRT1/Nrf2/NF‑κB signalling pathway.

Chemical Structure

Allisartan Isoproxil
CAS#947331-05-7

Theoretical Analysis

MedKoo Cat#: 329403

Name: Allisartan Isoproxil

CAS#: 947331-05-7

Chemical Formula: C27H29ClN6O5

Exact Mass: 552.1888

Molecular Weight: 553.02

Elemental Analysis: C, 58.64; H, 5.29; Cl, 6.41; N, 15.20; O, 14.47

Price and Availability

Size Price Availability Quantity
1mg USD 450.00 2 Weeks
5mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Allisartan Isoproxil; SB16810; SB-16810; SB 16810;
IUPAC/Chemical Name
((isopropoxycarbonyl)oxy)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazole-5-carboxylate
InChi Key
XMHJQQAKXRUCHI-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H29ClN6O5/c1-4-5-10-22-29-24(28)23(26(35)37-16-38-27(36)39-17(2)3)34(22)15-18-11-13-19(14-12-18)20-8-6-7-9-21(20)25-30-32-33-31-25/h6-9,11-14,17H,4-5,10,15-16H2,1-3H3,(H,30,31,32,33)
SMILES Code
ClC(N=C1CCCC)=C(C(OCOC(OC(C)C)=O)=O)N1CC(C=C2)=CC=C2C3=CC=CC=C3C4=NN=NN4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 553.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jin Q, Zhu Q, Wang K, Chen M, Li X. Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NF‑κB signalling pathway in diabetic cardiomyopathy rats. Mol Med Rep. 2021 Mar;23(3):215. doi: 10.3892/mmr.2021.11854. Epub 2021 Jan 26. PMID: 33495841; PMCID: PMC7845586. 2: Zhang G, Fan Y, Qiu Y, Zhou Z, Zhang J, Wang Z, Liu Y, Liu X, Tao J. Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial. Adv Ther. 2020 Aug;37(8):3551-3561. doi: 10.1007/s12325-020-01413-y. Epub 2020 Jun 24. PMID: 32583313. 3: Ling QS, Zhang SL, Tian JS, Cheng MH, Liu AJ, Fu FH, Liu JG, Miao CY. Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage. Acta Pharmacol Sin. 2021 Jun;42(6):871-884. doi: 10.1038/s41401-021-00684-7. Epub 2021 May 17. PMID: 34002042; PMCID: PMC8149727. 4: Zhang JQ, Yang GH, Zhou X, Liu JX, Shi R, Dong Y, Chen SB, Li YM. Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension. Medicine (Baltimore). 2019 Mar;98(12):e14907. doi: 10.1097/MD.0000000000014907. PMID: 30896643; PMCID: PMC6708765. 5: Yi W, Yan P, Lin S, Hao R, Wang Y, Yu J, Fang L, Zhu J, Zhao D, Tong S, Si Y, Ye T, Wu Z, Qin Z, Huang H, Deng C, Sun J, Wang Y. Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People. Clin Pharmacol Drug Dev. 2022 Jan;11(1):43-50. doi: 10.1002/cpdd.995. Epub 2021 Jul 8. PMID: 34240572. 6: Li Y, Li XH, Huang ZJ, Yang GP, Zhang GG, Zhao SP, Guo Y, Lu SJ, Ma JL, Meng FB, Chen P, Yuan H. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk. PLoS One. 2015 Feb 18;10(2):e0117560. doi: 10.1371/journal.pone.0117560. PMID: 25693004; PMCID: PMC4333341. 7: Zhang X, Zhao Z, Xu C, Zhao F, Yan Z. Allisartan ameliorates vascular remodeling through regulation of voltage-gated potassium channels in hypertensive rats. BMC Pharmacol Toxicol. 2021 Jun 9;22(1):33. doi: 10.1186/s40360-021-00498-7. PMID: 34108047; PMCID: PMC8188709. 8: Liu Y, Wang H, Cheng Y, Sun J, Qiao J, Lu H, Zhu L, Gong L, Ren J. A 26-week repeated-dose toxicity study of allisartan isoproxil in Sprague-Dawley rats. Drug Chem Toxicol. 2013 Oct;36(4):443-50. doi: 10.3109/01480545.2013.776580. Epub 2013 Mar 27. PMID: 23534454. 9: Dong X, He X, Wu J. Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting. Pharmacoeconomics. 2022 Dec;40(12):1187-1205. doi: 10.1007/s40273-022-01182-2. Epub 2022 Sep 8. PMID: 36071264. 10: Hou Y, Shao J, Fu Q, Li J, Sun J, He Z. Spray-dried nanocrystals for a highly hydrophobic drug: Increased drug loading, enhanced redispersity, and improved oral bioavailability. Int J Pharm. 2017 Jan 10;516(1-2):372-379. doi: 10.1016/j.ijpharm.2016.11.043. Epub 2016 Nov 20. PMID: 27880871. 11: Li X, Sun J, Guo Z, Zhong D, Chen X. Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. Drug Metab Dispos. 2019 Aug;47(8):843-853. doi: 10.1124/dmd.118.085092. Epub 2019 May 10. PMID: 31076412.